TY - JOUR
T1 - Hospital variation and outcomes after repeat hepatic resection for colorectal liver metastases
T2 - a nationwide cohort study
AU - de Graaff, Michelle R
AU - Klaase, Joost M
AU - den Dulk, Marcel
AU - Te Riele, Wouter W
AU - Hagendoorn, Jeroen
AU - van Heek, N Tjarda
AU - Vermaas, M
AU - Belt, Eric J Th
AU - Bosscha, Koop
AU - Slooter, Gerrit D
AU - Leclercq, Wouter K G
AU - Liem, Mike S L
AU - Mieog, J Sven D
AU - Swijnenburg, Rutger-Jan
AU - van Dam, Ronald M
AU - Verhoef, Cees
AU - Kuhlmann, Koert
AU - van Duijvendijk, Peter
AU - Gerhards, Michael F
AU - Gobardhan, Paul
AU - van den Boezem, Peter
AU - Manusama, Eric R
AU - Grünhagen, Dirk J
AU - Kok, Niels F M
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024/6
Y1 - 2024/6
N2 - BACKGROUND: Approximately 70% of patients with colorectal liver metastases (CRLM) experiences intrahepatic recurrence after initial liver resection. This study assessed outcomes and hospital variation in repeat liver resections (R-LR).METHODS: This population-based study included all patients who underwent liver resection for CRLM between 2014 and 2022 in the Netherlands. Overall survival (OS) was collected for patients operated on between 2014 and 2018 by linkage to the insurance database.RESULTS: Data of 7479 liver resections (1391 (18.6%) repeat and 6088 (81.4%) primary) were analysed. Major morbidity and mortality were not different. Factors associated with major morbidity included ASA 3+, major liver resection, extrahepatic disease, and open surgery. Five-year OS after repeat versus primary liver resection was 42.3% versus 44.8%, P = 0.37. Factors associated with worse OS included largest CRLM >5 cm (aHR 1.58, 95% CI: 1.07-2.34, P = 0.023), >3 CRLM (aHR 1.33, 95% CI: 1.00-1.75, P = 0.046), extrahepatic disease (aHR 1.60, 95% CI: 1.25-2.04, P = 0.001), positive tumour margins (aHR 1.42, 95% CI: 1.09-1.85, P = 0.009). Significant hospital variation in performance of R-LR was observed, median 18.9% (8.2% to 33.3%).CONCLUSION: Significant hospital variation was observed in performance of R-LR in the Netherlands reflecting different treatment decisions upon recurrence. On a population-based level R-LR leads to satisfactory survival.
AB - BACKGROUND: Approximately 70% of patients with colorectal liver metastases (CRLM) experiences intrahepatic recurrence after initial liver resection. This study assessed outcomes and hospital variation in repeat liver resections (R-LR).METHODS: This population-based study included all patients who underwent liver resection for CRLM between 2014 and 2022 in the Netherlands. Overall survival (OS) was collected for patients operated on between 2014 and 2018 by linkage to the insurance database.RESULTS: Data of 7479 liver resections (1391 (18.6%) repeat and 6088 (81.4%) primary) were analysed. Major morbidity and mortality were not different. Factors associated with major morbidity included ASA 3+, major liver resection, extrahepatic disease, and open surgery. Five-year OS after repeat versus primary liver resection was 42.3% versus 44.8%, P = 0.37. Factors associated with worse OS included largest CRLM >5 cm (aHR 1.58, 95% CI: 1.07-2.34, P = 0.023), >3 CRLM (aHR 1.33, 95% CI: 1.00-1.75, P = 0.046), extrahepatic disease (aHR 1.60, 95% CI: 1.25-2.04, P = 0.001), positive tumour margins (aHR 1.42, 95% CI: 1.09-1.85, P = 0.009). Significant hospital variation in performance of R-LR was observed, median 18.9% (8.2% to 33.3%).CONCLUSION: Significant hospital variation was observed in performance of R-LR in the Netherlands reflecting different treatment decisions upon recurrence. On a population-based level R-LR leads to satisfactory survival.
KW - Aged
KW - Colorectal Neoplasms/pathology
KW - Databases, Factual
KW - Female
KW - Hepatectomy/mortality
KW - Hospitals/statistics & numerical data
KW - Humans
KW - Liver Neoplasms/secondary
KW - Male
KW - Middle Aged
KW - Neoplasm Recurrence, Local
KW - Netherlands
KW - Reoperation
KW - Retrospective Studies
KW - Treatment Outcome
UR - http://www.scopus.com/inward/record.url?scp=85187371433&partnerID=8YFLogxK
U2 - 10.1016/j.hpb.2024.02.014
DO - 10.1016/j.hpb.2024.02.014
M3 - Article
C2 - 38461070
SN - 1365-182X
VL - 26
SP - 789
EP - 799
JO - International Hepato-Pancreato Biliary Association.
JF - International Hepato-Pancreato Biliary Association.
IS - 6
ER -